Absolutely! See all those BPs. They all have precision medicine programs (ADCs, t-cell enagers, small molecule drugs). They all compete with each other so that patients can have the maximum benefit. For each drug they successfully develop, LP has to take the cut. I assume LP can decide how much the cut should be.
Market Data 
Markets 
AI
